Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706641 · ClinicalTrials.gov registry record · NA
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
A NA study, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00706641 is a NA study that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 25 participants.
The verdict
NCT00706641, a NA study, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This pilot study is designed to determine feasibility and safety of treatment with dasatinib administered orally once daily for 4 weeks duration prior to radical cystectomy for urothelial carcinoma of the bladder.
Interventions
- DRUG Dasatinib
- PROCEDURE Radical Cystectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706641
The ClinicalTrials.gov registry entry for NCT00706641 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00706641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706641 about?
NCT00706641 is a clinical study titled "Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder". This pilot study is designed to determine feasibility and safety of treatment with dasatinib administered orally once daily for 4 weeks duration prior to radical cystectomy for urothelial carcinoma of the bladder.
What is the current status of trial NCT00706641?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2008-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00706641?
The interventions under investigation include: Dasatinib (DRUG), Radical Cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00706641?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.